

Full Portfolio Holdings\* as of August 31, 2023

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

| Security                             | Coupon | Maturity | Shares/Par | Value      | % of Net Assets |
|--------------------------------------|--------|----------|------------|------------|-----------------|
| <b>BASE CURRENCY</b>                 |        |          |            |            |                 |
| US DOLLAR                            |        |          | 647,478    | 647,478    | 0.46%           |
| <b>COMMON STOCKS</b>                 |        |          |            |            |                 |
| Eli Lilly & Co.                      |        |          | 21,025     | 11,652,055 | 8.25%           |
| UnitedHealth Group, Inc.             |        |          | 21,033     | 10,023,907 | 7.10%           |
| Merck & Co., Inc.                    |        |          | 73,709     | 8,032,807  | 5.69%           |
| Danaher Corp.                        |        |          | 23,943     | 6,344,895  | 4.49%           |
| Pfizer, Inc.                         |        |          | 166,777    | 5,900,570  | 4.18%           |
| Zoetis, Inc.                         |        |          | 20,632     | 3,930,602  | 2.78%           |
| Humana, Inc.                         |        |          | 7,951      | 3,670,420  | 2.60%           |
| Thermo Fisher Scientific, Inc.       |        |          | 6,460      | 3,598,866  | 2.55%           |
| Stryker Corp.                        |        |          | 12,607     | 3,574,715  | 2.53%           |
| Boston Scientific Corp.              |        |          | 65,804     | 3,549,468  | 2.51%           |
| HCA Healthcare, Inc.                 |        |          | 11,501     | 3,189,227  | 2.26%           |
| Vertex Pharmaceuticals, Inc.         |        |          | 8,834      | 3,077,236  | 2.18%           |
| Centene Corp.                        |        |          | 47,482     | 2,927,265  | 2.07%           |
| AstraZeneca plc                      |        |          | 40,751     | 2,763,733  | 1.96%           |
| Edwards Lifesciences Corp.           |        |          | 31,982     | 2,445,664  | 1.73%           |
| Molina Healthcare, Inc.              |        |          | 7,785      | 2,414,284  | 1.71%           |
| Abbott Laboratories                  |        |          | 23,231     | 2,390,470  | 1.69%           |
| Cencora, Inc.                        |        |          | 13,485     | 2,373,090  | 1.68%           |
| Agilent Technologies, Inc.           |        |          | 16,712     | 2,023,322  | 1.43%           |
| DexCom, Inc.                         |        |          | 19,702     | 1,989,508  | 1.41%           |
| ICON plc                             |        |          | 7,472      | 1,942,272  | 1.38%           |
| Daiichi Sankyo Co. Ltd.              |        |          | 62,635     | 1,844,830  | 1.31%           |
| Illumina, Inc.                       |        |          | 9,752      | 1,611,225  | 1.14%           |
| United Therapeutics Corp.            |        |          | 7,031      | 1,577,475  | 1.12%           |
| Regeneron Pharmaceuticals, Inc.      |        |          | 1,852      | 1,530,659  | 1.08%           |
| Biogen, Inc.                         |        |          | 5,504      | 1,471,549  | 1.04%           |
| Laboratory Corp. of America Holdings |        |          | 6,792      | 1,413,415  | 1.00%           |
| Becton Dickinson & Co.               |        |          | 5,019      | 1,402,560  | 0.99%           |
| UCB SA                               |        |          | 15,553     | 1,395,058  | 0.99%           |
| Eisai Co. Ltd.                       |        |          | 21,809     | 1,378,682  | 0.98%           |
| Encompass Health Corp.               |        |          | 18,747     | 1,331,787  | 0.94%           |
| Acadia Healthcare Co., Inc.          |        |          | 17,026     | 1,312,705  | 0.93%           |
| Insulet Corp.                        |        |          | 6,445      | 1,235,571  | 0.87%           |
| Bristol-Myers Squibb Co.             |        |          | 19,909     | 1,227,390  | 0.87%           |
| Chugai Pharmaceutical Co. Ltd.       |        |          | 39,100     | 1,191,842  | 0.84%           |
| Hologic, Inc.                        |        |          | 15,935     | 1,190,982  | 0.84%           |
| Novartis AG                          |        |          | 10,775     | 1,084,414  | 0.77%           |
| Waters Corp.                         |        |          | 3,289      | 923,551    | 0.65%           |
| Cytokinetics, Inc.                   |        |          | 26,060     | 910,536    | 0.64%           |
| Surgery Partners, Inc.               |        |          | 25,091     | 909,800    | 0.64%           |

Full Portfolio Holdings\* as of August 31, 2023

| Security                                 | Coupon | Maturity | Shares/Par | Value   | % of Net Assets |
|--|--------|----------|------------|---------|-----------------|
| Repligen Corp.                           |        |          | 5,145      | 894,767 | 0.63%           |
| Argenx SE                                |        |          | 1,767      | 887,900 | 0.63%           |
| Shockwave Medical, Inc.                  |        |          | 3,914      | 862,606 | 0.61%           |
| Exact Sciences Corp.                     |        |          | 10,305     | 862,219 | 0.61%           |
| agilon health, Inc.                      |        |          | 45,542     | 807,004 | 0.57%           |
| Alkermes plc                             |        |          | 26,994     | 787,955 | 0.56%           |
| GSK plc                                  |        |          | 43,811     | 767,391 | 0.54%           |
| Privia Health Group, Inc.                |        |          | 29,220     | 767,025 | 0.54%           |
| Elanco Animal Health, Inc.               |        |          | 61,014     | 744,371 | 0.53%           |
| Addus HomeCare Corp.                     |        |          | 8,424      | 738,785 | 0.52%           |
| Karuna Therapeutics, Inc.                |        |          | 3,784      | 710,484 | 0.50%           |
| Teleflex, Inc.                           |        |          | 3,317      | 705,659 | 0.50%           |
| Abcam plc                                |        |          | 30,059     | 679,935 | 0.48%           |
| Alnylam Pharmaceuticals, Inc.            |        |          | 3,404      | 673,379 | 0.48%           |
| Inari Medical, Inc.                      |        |          | 10,101     | 672,929 | 0.48%           |
| DiaSorin SpA                             |        |          | 5,928      | 625,977 | 0.44%           |
| Genmab AS                                |        |          | 1,624      | 622,211 | 0.44%           |
| Gilead Sciences, Inc.                    |        |          | 8,115      | 620,635 | 0.44%           |
| Ascendis Pharma AS                       |        |          | 6,083      | 596,256 | 0.42%           |
| Tecan Group AG                           |        |          | 1,418      | 565,384 | 0.40%           |
| Avantor, Inc.                            |        |          | 25,939     | 561,579 | 0.40%           |
| Bio-Techne Corp.                         |        |          | 7,081      | 555,150 | 0.39%           |
| Veracyte, Inc.                           |        |          | 20,469     | 540,382 | 0.38%           |
| Verona Pharma plc                        |        |          | 25,773     | 500,769 | 0.35%           |
| Seagen, Inc.                             |        |          | 2,399      | 494,362 | 0.35%           |
| Moderna, Inc.                            |        |          | 4,316      | 488,010 | 0.35%           |
| Immunocore Holdings plc                  |        |          | 8,372      | 471,092 | 0.33%           |
| Zai Lab Ltd.                             |        |          | 16,801     | 427,921 | 0.30%           |
| Genus plc                                |        |          | 14,365     | 422,602 | 0.30%           |
| Sarepta Therapeutics, Inc.               |        |          | 3,303      | 399,696 | 0.28%           |
| QuidelOrtho Corp.                        |        |          | 4,702      | 387,257 | 0.27%           |
| PTC Therapeutics, Inc.                   |        |          | 9,658      | 381,491 | 0.27%           |
| Vaxcyte, Inc.                            |        |          | 7,200      | 373,824 | 0.26%           |
| Revolution Medicines, Inc.               |        |          | 10,910     | 370,613 | 0.26%           |
| Merus NV                                 |        |          | 16,475     | 368,546 | 0.26%           |
| ImmunoGen, Inc.                          |        |          | 23,112     | 366,094 | 0.26%           |
| Otsuka Holdings Co. Ltd.                 |        |          | 9,400      | 357,122 | 0.25%           |
| Celldex Therapeutics, Inc.               |        |          | 12,540     | 349,866 | 0.25%           |
| Sage Therapeutics, Inc.                  |        |          | 16,553     | 331,060 | 0.23%           |
| Owens & Minor, Inc.                      |        |          | 19,527     | 330,006 | 0.23%           |
| Morphic Holding, Inc.                    |        |          | 5,857      | 322,604 | 0.23%           |
| Apellis Pharmaceuticals, Inc.            |        |          | 7,552      | 318,770 | 0.23%           |
| Guardant Health, Inc.                    |        |          | 7,642      | 298,649 | 0.21%           |
| Hapvida Participacoes e Investimentos SA |        |          | 341,335    | 293,633 | 0.21%           |
| Inspire Medical Systems, Inc.            |        |          | 1,240      | 281,331 | 0.20%           |

Full Portfolio Holdings\* as of August 31, 2023

| Security  | Coupon | Maturity | Shares/Par | Value              | % of Net Assets |
|---|--------|----------|------------|--------------------|-----------------|
| Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.                |        |          | 28,300     | 276,059            | 0.20%           |
| Syndax Pharmaceuticals, Inc.                                    |        |          | 13,900     | 257,289            | 0.18%           |
| Blueprint Medicines Corp.                                       |        |          | 4,787      | 238,680            | 0.17%           |
| Ultragenyx Pharmaceutical, Inc.                                 |        |          | 5,612      | 206,465            | 0.15%           |
| Aclaris Therapeutics, Inc.                                      |        |          | 25,159     | 188,189            | 0.13%           |
| Prothena Corp. plc  |        |          | 3,516      | 185,715            | 0.13%           |
| Smith & Nephew plc  |        |          | 7,828      | 105,639            | 0.07%           |
| Ono Pharmaceutical Co. Ltd.                                     |        |          | 3,076      | 58,112             | 0.04%           |
| Contra Abiomed, Inc.  |        |          | 885        | 903                | 0.00%           |
| <b>FOREIGN CURRENCY</b>   |        |          |            |                    |                 |
| BRAZILIAN REAL  |        |          | 226,512    | 45,741             | 0.03%           |
| SWISS FRANC   |        |          | 35         | 40                 | 0.00%           |
| EURO CURRENCY   |        |          | 19         | 21                 | 0.00%           |
| DANISH KRONE  |        |          | 34         | 5                  | 0.00%           |
| HONG KONG DOLLAR  |        |          | 5          | 0.58               | 0.00%           |
| JAPANESE YEN  |        |          | 1          | 0.01               | 0.00%           |
| POUND STERLING  |        |          | (0.16)     | (0.20)             | 0.00%           |
| <b>REPURCHASE AGREEMENTS</b>                                    |        |          |            |                    |                 |
| FIXED, Inc. CLEARING CORP.REPO                                  |        | 9/1/2023 | 164,051    | 164,051            | 0.12%           |
| <b>DERIVATIVES - FOREIGN CURRENCY EXCHANGE CONTRACTS (SPOT)</b> |        |          |            |                    |                 |
| EURO CURRENCY   |        | 9/1/2023 | (13,106)   | 106                | 0.00%           |
| SWISS FRANC   |        | 9/1/2023 | (6,941)    | 48                 | 0.00%           |
| POUND STERLING  |        | 9/1/2023 | (7,323)    | 35                 | 0.00%           |
| SWISS FRANC   |        | 9/1/2023 | (3,521)    | 24                 | 0.00%           |
| DANISH KRONE  |        | 9/5/2023 | (32,137)   | 2                  | 0.00%           |
| <b>TOTAL INVESTMENTS</b>  |        |          |            | <b>139,718,311</b> | <b>98.93%</b>   |
| <b>OTHER ASSETS LESS LIABILITIES</b>                            |        |          |            | <b>1,512,739</b>   | <b>1.07%</b>    |
| <b>TOTAL NET ASSETS</b>   |        |          |            | <b>141,231,050</b> | <b>100.00%</b>  |

\* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on [www.hartfordfunds.com](http://www.hartfordfunds.com) for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

**Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting [hartfordfunds.com](http://hartfordfunds.com). Please read it carefully before investing.**

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22